Severe Asthma Biologics Tied to Fewer Heart Events

The drugs that keep severe asthma under control may be doing quiet work for the heart at the same time. An analysis presented this week at the CHEST Annual Meeting in Phoenix found that adults with severe asthma taking severe asthma biologics had meaningfully lower rates of heart attacks, strokes, heart failure and death than similar patients who were not on the drugs. The study, reported by Healio on Monday, matched 9,805 biologic users with an equal number of non-users drawn from the TriNetX global health research network; the pooled group averaged 53 years old and was roughly two-thirds women.

The heart numbers behind severe asthma biologics

Across a three-year window, the researchers tracked a composite of major cardiovascular events: heart attack, stroke, heart failure or death from any cause. Every outcome favored the biologic group, and all of them reached statistical significance, lead author Soham Nadkarni, a resident physician at the University of Tennessee Health Science Center, said, according to Healio. Taken together, the chance of a major event came in roughly a quarter lower for patients taking severe asthma biologics.

The sharpest drops showed up in heart failure and mortality. Heart failure risk fell by 44 percent, and deaths from any cause were cut roughly in half. Among the control group, about one in 10 patients developed heart failure within three years, a figure Nadkarni flagged because heart failure is the cardiovascular complication that asthma raises the most.

Not every drug performed identically

Benralizumab and dupilumab, two widely used severe asthma biologics, posted the strongest results. Major events occurred in 18.4 percent of benralizumab patients against 27.8 percent of their matched controls, and 17.5 percent against 24.9 percent for dupilumab. The heart failure reduction reached 50 percent with benralizumab and 35 percent with dupilumab. Stroke risk was significantly lower with both drugs, and dupilumab also showed the lowest heart attack risk of the group. Mepolizumab and omalizumab pointed in the same direction with smaller effects. Tezepelumab, the newest of the five, missed significance on the composite measure but still showed a strong heart failure benefit. For transparency, Nadkarni noted that all-cause mortality with omalizumab was the single estimate out of more than 40 comparisons to land above one, a result he said should not be over-interpreted either way.

Why the heart would benefit

The explanation may be simpler than the pharmacology. The five drugs block different immune pathways, which makes it hard to credit one single mechanism, Nadkarni said. The likelier story, he suggested, is what the drugs share: fewer flare-ups and less exposure to oral steroids, both of which tax the cardiovascular system. Severe asthma itself carries cardiovascular baggage: the chronic inflammation behind the disease and the repeated bursts of oral steroids used to calm it both strain the heart and blood vessels over time. That reading gets backup from a separate nationwide Belgian study published in The Lancet Regional Health Europe, which followed more than one hundred seventy thousand adults and found users of severe asthma biologics had a significantly lower risk of death and of several cardiovascular diseases than similar patients not taking the drugs.

What to make of it

Caution is warranted. The findings come from propensity-matched observational data, not a randomized trial, and the analysis did not account for eosinophil counts, steroid doses, exacerbation history or lung function. Patients who end up on a biologic may also be healthier in ways the data could not capture, since getting one requires referral, approval and years of regular visits. Nadkarni described the results as hypothesis-generating, according to Healio, and said nobody should prescribe severe asthma biologics for heart protection on this evidence. For clinicians, his practical advice was to treat severe asthma as a systemic inflammatory condition: keep an eye on blood pressure, lipids and blood sugar, and ask about heart failure symptoms early, since breathlessness during exertion is easy to blame on the asthma.

For patients living with both conditions, severe asthma biologics look reassuring rather than prescriptive. Starting a biologic does not appear to add cardiovascular risk, Nadkarni said. The next studies, he said, should adjust for eosinophil counts and steroid burden and follow patients longer.

Sources: Healio; The Lancet Regional Health Europe via PubMed Central.